CYP 8.57% 19.0¢ cynata therapeutics limited

On track for Phase 2 clinical trials

  1. 471 Posts.
    lightbulb Created with Sketch. 34

    Cynata Therapeutics (ASX:CYP) on track for Phase 2 clinical trials



    • Cynata Therapeutics (CYP) has released its December 2019 quarterly report, primarily outlining positive operations
    • Highlights for the biotech company include planning multiple Phase 2 clinical trials and receiving a notice of allowance from the Canadian Intellectual Property Office
    • Moving forward with the Phase 2 trials places Cynata one step closer to commercialising its products

    Click to view full article

 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
19.0¢
Change
0.015(8.57%)
Mkt cap ! $34.13M
Open High Low Value Volume
18.5¢ 19.0¢ 18.5¢ $7.936K 41.94K

Buyers (Bids)

No. Vol. Price($)
1 37413 18.0¢
 

Sellers (Offers)

Price($) Vol. No.
19.0¢ 7290 1
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
19.5¢
  Change
0.015 ( 11.4 %)
Open High Low Volume
18.5¢ 19.5¢ 18.5¢ 5805
Last updated 15.29pm 29/03/2024 ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.